U.S. Markets open in 1 hr 20 mins

Lantheus Holdings, Inc. (LNTH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.91-0.10 (-0.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.01
Open21.01
Bid20.00 x 1100
Ask21.99 x 800
Day's Range20.77 - 21.20
52 Week Range10.52 - 21.99
Volume516,726
Avg. Volume583,246
Market Cap1.41B
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Lantheus Expands R&D Leadership Team with Key New Hires
    Business Wire

    Lantheus Expands R&D Leadership Team with Key New Hires

    Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko. Both report directly to Lantheus’ Chief Medical Officer, Istvan Molnar, MD.

  • Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
    Business Wire

    Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel

    Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be retained in an advisory capacity. His responsibilities will be assumed by Daniel Niedzwiecki, who has been with the Company since 2013 and will report directly to Mary Anne Heino, President and CEO.

  • Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
    Business Wire

    Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria

    Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc.